LOGIN  |  REGISTER
Compass Therapeutics

GE HealthCare management to present at September investor conferences

August 21, 2024 | Last Trade: US$88.53 1.74 2.00

CHICAGO / Aug 21, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) announced today that management will present at the following September investor conferences.

  • 2024 Wells Fargo Healthcare Conference in Boston on September 4, 2024 at 10:15 am ET/9:15 am CT
  • Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5, 2024 at 1:05 pm ET/12:05 pm CT

These events can be accessed at the GE HealthCare Investor Relations website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB